Proteasome inhibition reduces donor-specific antibody levels.

Everly, M J; Everly, J J; Susskind, B; Brailey, P; Arend, L J; Alloway, R R; Roy-Chaudhury, P; Govil, A; Mogilishetty, G; Rike, A H; Cardi, M; Wadih, G; Brown, E; Tevar, A; Woodle, E S

Everly, M J; Everly, J J; Susskind, B; Brailey, P; Arend, L J; Alloway, R R; Roy-Chaudhury, P; Govil, A; Mogilishetty, G; Rike, A H; Cardi, M; Wadih, G; Brown, E; Tevar, A; Woodle, E S.

Affiliation

Everly MJ; University of Cincinnati College of Medicine, and The Christ Hospital, Cincinnati, OH 45267-0558, USA.

Transplant Proc ; 41(1): 105-7, 2009.

Article in En | MEDLINE | ID: mdl-19249489

Subject(s)

Isoantibodies/blood; Kidney Transplantation/immunology; Proteasome Inhibitors; Boronic Acids/adverse effects; Boronic Acids/therapeutic use; Bortezomib; Follow-Up Studies; Graft Rejection/chemically induced; Graft Rejection/immunology; Humans; Pancreas Transplantation/immunology; Protease Inhibitors/adverse effects; Pyrazines/adverse effects; Pyrazines/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Kidney Transplantation / Proteasome Inhibitors / Isoantibodies Type of study: Observational_studies / Prognostic_studies Limits: Humans Language: En Journal: Transplant Proc Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google